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ABSTRACT 
Purpose: The aim in this study was to develop a Patient Reported Outcome Measure (PROM) for clinical genetics services. 
Methods: Previous research was used to develop a draft 84-item questionnaire, which was completed by 527 members of patient support groups. Responses were subjected to exploratory factor analysis (EFA). Parallel analysis was used to identify the number of factors to extract using oblique rotation. 24 questions were selected to form the Genetic Counseling Outcome Scale (GCOS-24). 241 patients completed a questionnaire pack before and after attendance at a genetics clinic that included the GCOS-24, and validated measures of health locus of control, perceived personal control, anxiety, depression, satisfaction with life and authenticity. Concurrent validity of the GCOS-24 was assessed using bivariate correlation. Sensitivity to change of the GCOS-24 was assessed using analysis of variance.
Results: EFA identified a single overarching construct consisting of 7 dimensions. Internal consistency (α= 0.87) and test-retest reliability (0.86) are good. The GCOS-24 demonstrates convergent and divergent validity, and sensitivity to change over time with a medium-to-large effect size (Cohen’s d = 0.70).   
Conclusion: The GCOS-24 has potential as a clinical genetics-specific PROM. 
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INTRODUCTION
Evaluating interventions in clinical genetics is difficult because there is little agreement about suitable outcome measures (1-3).  In other specialties, measures of health status combined with measures of Health Related Quality of Life (HRQoL) are commonly used (4). However, although pharmaceutical and surgical options may become important in some genetic conditions (5), measures of health status are unlikely to be generally applicable because interventions offered by clinical genetics rarely affect health status (3).  There is also evidence that health status is not valued as an outcome from clinical genetics, but that HRQoL is valued by patients and clinicians (6). HRQoL measures have been recommended as useful in clinical trials in medical genetics (7).

HRQoL is usually measured using Patient Reported Outcome Measures (PROMs). PROMs are short self-completion questionnaires capturing aspects of patient health status or HRQoL that come directly from the patient, without interpretation of responses by a clinician (8). Generic measures of HRQoL are available, but there is no condition-specific PROM of HRQoL for genetic conditions that captures all important patient benefits (9,10).

Our previous qualitative research suggests that patient benefits from clinical genetics could be summarised using a new construct, empowerment (9,10), defined as the beliefs that one:
(1)	Can make important life decisions in an informed way (decisional control)
(2)	Has sufficient information about the condition, including risks to oneself and one’s relatives, and any treatment, prevention and support available (cognitive control) 
(3)	Can make effective use of the health and social care systems for the benefit of the whole family (behavioural control)
(4)	Can manage one’s feelings about having a genetic condition in the family (emotional regulation)
(5)	Can look to the future having hope for a fulfilling family life, for oneself, one’s family, and/or one’s future descendents (hope) 
Empowerment can be considered an aspect of HRQoL (11). When compared with outcome measures used in evaluations of clinical genetics, empowerment is conceptually most similar to the construct captured by the Perceived Personal Control questionnaire (PPC) (12). However, PPC does not capture all patient benefits summarised in empowerment e.g. emotional regulation and benefits to other relatives (9,10).

The aim in this study was to develop a robust, theory-driven clinical genetics-specific PROM. The theoretical framework driving PROM development in this study is the grounded theory model of empowerment (9,10). Specific objectives were to (a) develop an instrument to measure empowerment (b) perform preliminary psychometric evaluation of the instrument, including reliability, some construct validity and sensitivity to change. This PROM could be useful as a clinical genetics-specific measure of HRQoL for use in evaluating clinical genetics services.

METHODS
Questionnaire Construction (item pool)
An item pool of 84 questions (Table 1) was generated using (i) qualitative data (9,10) (ii) the PPC items (12) and (iii) the emotional representations sub-scale of the Revised Illness Perceptions questionnaire (13) adapted for use in genetic conditions. To maximise content validity, items were designed to comprehensively sample from the qualitative data, resulting in a large item pool with approximately equal numbers of positively and negatively worded items. Ease of understanding and face validity was checked in one focus group and 4 interviews with patient group representatives, resulting in rewording of some items. 

Study 1: Factor analysis, reliability and development of short questionnaire
Factor analysis was conducted to inform item selection for the final questionnaire. Some psychometricians recommend sample sizes of at least 5 times the number of items to be analysed (14,15), in this case, 420 participants. To facilitate large-scale data collection, paper and online versions of the 84-item questionnaire were created. A sample of people was sought for whom having a genetic condition in the family was a current concern, but amongst whom levels of empowerment were not likely to change significantly. This stability was required for test re-test reliability testing. Members of patient support groups for genetic conditions were targeted, rather than a patient sample as it was expected that levels of empowerment in a patient sample would be more likely to change over time. 

Patient support groups were recruited, using approved informed consent procedures by Genetic Alliance UK (GAUK), a UK alliance of over 130 patient organisations supporting families affected by genetic conditions. Organisations were asked by GAUK, by letter or email, to recruit their members into the study.  Whether paper questionnaires were sent to members, or whether members were sent an e-mail link to the online questionnaire, or both, was decided at the discretion of each organisation. 

Study 2: Construct validity and sensitivity to change of the GCOS-24
To test sensitivity to change over time, and construct validity of the GCOS-24, all patients (>18 years old) attending a CGS for a first appointment between February and July 2010 were asked to participate in the study by the clinical team, using approved informed consent procedures. If the person referred was a child, his/her parent was approached. Parents of affected children can be thought of as “patients” in clinical genetics, since they may be at risk for having an affected child in their next pregnancy. Participants were sent a questionnaire pack prior to their first CGS appointment, which included the GCOS-24, the Multidimensional Health Locus of Control Scales (MHLC) (16), the State-Trait Anxiety Inventory short form (STAI-6) (17), the Perceived Personal Control scale (PPC) (12), the Personal Health Questionnaire (PHQ-9) (a measure of depression) (18), the Satisfaction with Life questionnaire (SWL) (19) and the Authenticity scale (20). Patients indicating on their first questionnaire that they were happy to be sent a further questionnaire 2-4 weeks after their appointment, were sent a copy of the same questionnaire pack. For this study, all participants were sent a paper questionnaire pack in the post.

RESULTS
Study 1: Factor analysis, reliability and development of short questionnaire
Sample characteristics:

In total, 549 participants completed the 84-item questionnaire. 290 responses (52.8%) were on paper, and 259 responses (47.2%) were online. Twenty-two questionnaires completed online were excluded because of excessive (>5%) missing data. All completed paper questionnaires were included. For questionnaires with minimal missing data (<5%), the mean of all responses from other subjects on a given item was used to “impute” missing values. The final sample size was 527. Because the questionnaire was available online, and because for ethical reasons, the research team did not have access to patient support group mailing lists, we cannot report accurate participation rates. We estimate participation rates to be 16.7% based upon the number of paper questionnaires requested and returned. This is likely to be an underestimate, because all those sent a paper questionnaire also had the option to complete the questionnaire online, and may have done so in preference.

Respondents described themselves as predominantly female (79.5%) and White British (89.6%). 35.2% were aged 17-40 years; 33.4% were aged 40–49 years; 31.4% were aged 50–80 years. A wide range of genetic conditions was represented (see Table 2). 219 respondents (41.5%) described themselves as affected by a genetic condition, 352 (66.8%) as the parent of an affected child; 122 (23.1%) as concerned that they may be at risk for developing a genetic condition themselves, and 318 (60.3%) as concerned that they may be at risk for having an affected child. There were, of course, overlaps between these four groups.
 
Exploratory factor analysis:

Maximum likelihood exploratory factor analysis (EFA) was conducted, followed by oblique (promax) rotation (21-23), using SPSS for Windows 16.0 (24). Oblique rotation was used because (a) factors were theoretically expected to correlate based on the theoretical structure of the empowerment construct (9,10), and (b) it was found to provide a solution closer to simple structure than varimax rotation, providing empirical evidence that factors are likely to be correlated in this sample. Bartlett’s test suggested the data were suitable for EFA, χ2 = 25021.344, p < 0.001. The Kaiser-Meyer-Olkin test (25) indicated that a factorial solution could be found in the item pool (0.946). The sample size exceeded Gorsuch’s 5 participants per item recommendation (14). 

Methods for deciding how many factors to extract in EFA include the scree test, Kaiser’s eigenvalues-greater-than-one test and Parallel Analysis (PA) (15, 26).  Of these methods, recent evidence suggests PA to be the most reliable. PA was conducted using SPSS syntax to randomly generate 1000 random data matrices, each with 527 cases and 84 variables (26). In the real dataset, the first 15 eigenvalues (and associated % of variances) were 23.47 (27.9%), 6.02 (7.2%), 3.23 (3.8%), 2.80 (3.3%%), 2.43 (2.9%), 2.11 (2.5%), 1.85 (2.2%), 1.56 (1.9%), 1.46 (1.7%), 1.36 (1.6%), 1.29 (1.5%), 1.19 (1.4%), 1.13 (1.3%), 1.11 (1.3%), 1.05 (1.24%). These eigenvalues exceeded the seventh but not eighth eigenvalues that emerged from PA (respectively, 1.67 and 1.64), suggesting an optimal 7-factor structure (as only seven factors are larger than would be expected from pure chance dataset characteristics). On this basis, seven factors were extracted and rotated (Table 1). Factor inter-correlations are shown in Table 3.

Theoretically, each of the seven factors should exist under a super-ordinate empowerment construct (9,10). To test this, we conducted a higher order factor analysis, by assigning each participant a factor score on each of the seven extracted factors, and submitting these factor scores to maximum likelihood EFA. The eigenvalues (and associated % of variances) were 3.17 (45.3%), 1.23 (17.5%), 0.95 (13.6%), 0.63 (9.1%), 0.49 (7.1%), 0.31 (4.4%), 0.22 (3.1%). PA indicated that only the first eigenvalue exceeded the eigenvalues that emerged from 95% of the random datasets (respectively, the first and second eigenvalues were 1.23 and 1.14). This indicates that the seven factors exist under a single higher order construct, “empowerment”.

Creating the shorter questionnaire:

The aim was to develop a short questionnaire that represents the entire outcome domain, so 3-5 items were selected from each factor. Items were not selected solely on the basis of the highest factor loadings, as is commonly done, because for some of the factors, the items with the highest factor loadings were judged to be too similar to each other, or to include too many negatively worded items. In addition, although the factor structure was stable as sample size grew over 450, the rank order of items within factors was subject to sampling variation. Items were selected for sub-scales, informed by (a) the rank order of items within factors following EFA, (b) those issues that our qualitative research suggested were most troubling for families affected by genetic conditions e.g. feelings of guilt; concern about how to communicate to other at risk family members about the condition (9,10,27-29) and (c) clinical judgement about which items would provide useful information to clinicians about interventions to improve patient outcomes. This resulted in a final questionnaire, the Genetic Counseling Outcome Scale (GCOS-24), composed of 24 items (Table 1). Item distributions are shown in Table 4.

Reliability analyses:
Internal consistency for the questionnaire is 0.87.  A test retest reliability study was conducted on a sample of 64 participants, asked to complete the 24-item questionnaire at two time-points with an interval of 2-10 weeks.  Test retest reliability was estimated by an intraclass correlation obtained through the use of one-way analysis of variance and was found to be 0.86. 

Study 2: GCOS-24: Construct validity and sensitivity to change

Sample characteristics:
In total, 395/1205 (32.8%) patients invited to participate in the study completed and returned a questionnaire pack prior to their first CGS appointment (T0). 374 of these (94.7%) attended for their appointment, and of these, 241 (64.4%) completed a second questionnaire pack 2-4 weeks after their CGS appointment (T1). For questionnaires with minimal missing data (<5%), prorating was used to “impute” missing values. 

Respondents at T0 ranged in age from 18–79 years, and were predominantly female (74.4%) and White British (86.6%). A number of different types of genetic conditions were represented, as follows: 238 (60.3%) cancer; 39 (9.9%) dysmorphology / learning disability; 18 (4.6%) neurological / neuromuscular conditions; 35 (8.9%) cardiac conditions; 12 (3%) genetic eye conditions; 12 (3%) chromosome abnormalities and 41 (10.4%) other conditions. 155 respondents (39.2%) were referred because they were affected by a (potentially) genetic condition; 62 (15.7%) because they were the parent of an affected child; 159 (40.3%) because they might be at risk for developing a genetic condition themselves; 15 (3.8%) because they might be at risk for having an affected child; 3 (0.8%) for a predictive genetic test (data was missing for one person). There were no significant differences in gender, ethnicity, condition type or reason for referral between the samples responding at (a) baseline only (T0) and at (b) both baseline and Time 1 (T0+T1). However, the T0+T1 participants were significantly older than T0 only participants (t = -4.69 (390 df); p < .001 (–8.73 < 95% CI < - 3.57)).”

Construct validity and sensitivity to change:
We explored the relationships between empowerment and gender, ethnicity, condition type, reason for referral, and whether patients described themselves as active in a patient support group at baseline (n=395). Patients who described themselves as active in a patient support group were significantly more empowered than those who did not (F = .152; p = .014; 2.13 < 95% CI < 18.72). This provides some evidence of known-groups validity.

To test the relationships between empowerment and health locus of control (HLC); PPC, anxiety; depression; SWL; and authenticity, we correlated GCOS-24 scores with measures of these constructs at baseline (n=395) (See Table 5). As expected, empowerment was significantly positively correlated with internal HLC, PPC, authenticity and SWL, with the highest correlation being with PPC. PPC explains ~30% of the variance in empowerment; SWL explains ~16.8%, internal HLC explains ~7.3%, and authenticity explains 4.2%. This demonstrates good convergent validity. As expected, empowerment was significantly negatively correlated with depression (explaining ~10.5% of the variance in empowerment), and was not significantly correlated with either fate HLC or powerful others HLC, demonstrating good divergent validity. Unexpectedly, empowerment was significantly positively correlated with anxiety. However, the correlation was low, and less significant than the other significant correlations, with anxiety explaining only ~1.8% of the variance in empowerment.

To further explore construct validity, we tested empowerment scores before and after clinic attendance using a paired samples t-test (n=241). Levels of empowerment were significantly higher following clinic attendance. This also provides evidence of sensitivity to change of the GCOS-24, with a medium-to-large effect size (Cohen’s d = 0.70).  

DISCUSSION
This research has developed a new 24-item genetics-specific PROM, the GCOS-24, which captures the construct of empowerment (9, 10), and demonstrates good internal consistency, test-retest reliability, sensitivity to change, and some evidence of construct validity. The empowerment construct captured by the GCOS-24 combines some aspects of other constructs that have even operationalized in measurement scales, such as PPC (12) and decisional conflict (30), as well bringing in other dimensions not traditionally included in PROMs such as hope. An important strength of this research is that it is grounded in extensive qualitative research with families affected by genetic conditions, and genetics clinicians. Items in the GCOS-24 reflect outcomes from using clinical genetics that are valued by those stakeholders (9,10,27-29, 31).  The questionnaire differs from questionnaires developed to evaluate clinical genetics constructed using a priori theorizing e.g. PPC.  

PROMs capturing patient empowerment have been developed and validated, specific to some conditions e.g. the Empowerment Scale (mental healthcare) (32), the Diabetes Empowerment Scale  (diabetes) (33) and the Patient Empowerment Scale (cancer) (34). The present research has developed a PROM of patient empowerment specific to genetic conditions for use in evaluating clinical genetics services. The GCOS-24 may also be useful for collecting PROMs data in routine clinical genetics practice. There are moves in the UK towards using PROMs to evaluate routine clinical practice for continuous quality improvement (35, 36).  

An important strength of this research is the large sample sizes achieved. Although estimated participation rates for the EFA were low in Study 1, this is unlikely to significantly affect the findings, because such a large number of people for whom having a genetic condition in the family is a current issue did complete the questionnaire and the factor structure was stable. Furthermore, the GCOS-24 is designed to provide information to clinicians on specific patient benefits, so items in the questionnaire may be useful to clinicians wishing to develop new interventions to improve patient benefits. 

One limitation of this research is that the factor analysis was conducted with a sample of patient support group members (Study 1). Study 2 provided evidence suggesting that members of patient support groups may be more empowered than patients who are not support group members, and so the Study 1 sample could be a homogeneous sample in terms of empowerment, which may affect the validity of the factorial analysis. Although the Study 1 sample, on the face of it, appears to represent a broad range of genetic conditions, there was no way of confirming whether participants actually came from families affected by a genetic condition. Also, since participation in patient support groups, as well as participation in both Study 1 and Study 2 was voluntary, participants may not represent all patients. 

Another limitation of this study is that the samples in both Studies 1 and 2 were over-represented by people describing themselves as female and White British. Furthermore, the sample in Study 2 was (a) over-represented by patients referred for familial cancer risks, with very small numbers of patients in some of the other categories e.g. neurological / neuromuscular conditions, chromosome abnormalities and genetic eye conditions and (b) under-represented by patients referred for reproductive risks and predictive genetic testing. It is not known whether or not this reflects the profile of new referrals to the centre, because for ethical reasons, we could not collect any data from patient files for patients who declined to participate. In addition, although 43% of participants were offered a genetic test in clinic, none of these had a result from this by the time they completed their post-clinic questionnaire. 

In conclusion, psychometric testing suggests that the GCOS-24 has potential to be a useful PROM to evaluate clinical genetics services. However, as is commonly the case with new psychometric instruments, further testing is needed before the GCOS-24 can be unreservedly recommended for routine evaluation in clinical genetics. In particular, longer follow-up studies, with non-cancer as well as cancer genetics samples, are required to explore the impact of genetic counseling and genetic test results on patient empowerment in clinical genetics. It will also be important to explore the impact of reproductive genetic counseling and testing on patient empowerment, and to test discriminant validity of the GCOS-24 in intervention studies (37, 38). Now that the GCOS-24 is in the public domain we plan to set up an anonymised data repository for future analysis and look forward to hearing from interested parties, who would like to contribute to this repository and/or collaborate in future research. A collaboration of this kind is currently underway with colleagues in Scotland who will be using the GCOS-24 for a service evaluation of clinical genetics practice during 2011, and will be contributing the anonymised data collected to our repository.
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